Table 3.

Mortality in remdesivir efficacy trials

	Trial	No oxygen	Low-standard flow oxygen	High flow oxygen	NIMV	Mechanical ventilation
Mortality	Wang et al.[13]	NT	HR: 0.82 (8.5% vs. 10.3%)	HR: 1.4 (37.9% vs. 30.0%)
	ACTT [14▪▪]	HR: 0.82 (4.1% vs. 4.8%)	HR: 0.30 (4.0% vs. 12.7%)	HR: 1.02 (21.2% vs. 20.4%)		HR: 1.13 (21.9% vs. 19.3%)
	SIMPLE-Moderate [15]	HR: 0.64 (1.3% vs. 2.0%)	NT	NT	NT	NT
	Solidarity [16]	HR: 0.90 (2.0% vs. 2.1%)	HR: 0.85 (12.2% vs. 13.8%)		HR: 1.2 (43.0% vs. 37.8%)

This population was not part of the trial population evaluated in the trial.

ACTT, Adaptive COVID-19 Treatment Trial; HR, hazard ratio; NT, not tested; NIMV, non-invasive mechanical ventilation.